Robert Sorenson
Ophthalmology · Hemet, CANPI 1366422917
Payments from drug & device makers
Across 261 payments — averaging $1044.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$193K
- AbbVie$24K
- Kala Pharmaceuticals, Inc.$20K
- Sun Pharmaceutical Industries Inc.$19K
- Bausch Health US, LLC$6K
- Eyepoint US, Inc.$4K
- plus $6K from 14 others
What the payments were for
- Consulting fees$90017%
- Speaking & faculty fees$1,50029%
- Travel & lodging$83516%
- Food & beverage$1,99438%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 154 | $193,472 |
| AbbVie(2 entities) | 30 | $24,205 |
| Kala Pharmaceuticals, Inc. | 8 | $20,355 |
| Sun Pharmaceutical Industries Inc. | 10 | $19,094 |
| Bausch Health US, LLC | 2 | $6,000 |
| Eyepoint US, Inc. | 4 | $3,824 |
| Shire North American Group Inc | 4 | $3,349 |
| Alcon | 28 | $1,686 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $173 |
| Rxsight Inc | 4 | $103 |
| NEW World Medical,inc. | 1 | $66 |
| Tarsus Pharmaceuticals, Inc. | 2 | $64 |
| Amgen(2 entities) | 4 | $62 |
| Aerie Pharmaceuticals, Inc. | 3 | $56 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Ivantis, Inc | 1 | $28 |
| Bausch & Lomb Americas Inc. | 1 | $22 |
| Ocular Therapeutix, Inc. | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Harrow Eye, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent inject Trabecular Micro-Bypass Stent System$1,500
- Clareon$1,012
- DEXYCU$900
- iDoseTR$177
- AcrySof IQ VIVITY IOL$102
How this compares
$272,646 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 21 | $30,029 |
| RocklatanNetarsudil Mesylat/Latanoprost | 37 | $28,395 |
| XiidraLifitegrast | 15 | $21,584 |
| LumiganBimatoprost | 38 | $18,216 |
| Cyclosporine | 32 | $16,919 |
| Prednisolone Acetate | 528 | $14,811 |
| Alphagan PBrimonidine Tartrate | 38 | $13,948 |
| Latanoprost | 687 | $11,679 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $9,028 |
| MoxifloxacinMoxifloxacin Hcl | 401 | $8,163 |
| Ketorolac Tromethamine | 400 | $6,035 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $5,769 |
| RhopressaNetarsudil Mesylate | 12 | $5,438 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 237 | $4,901 |
| Travoprost | 37 | $4,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $24,205 | $67,963108 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $56 | $33,83349 claims |
| Bausch & Lomb Americas Inc.Xiidra | $22 | $21,58415 claims |
| AlconSimbrinza | $1,686 | $9,02820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Hemet
- Dagny LuongHemet$1.6M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.